289718-03-2Relevant academic research and scientific papers
BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS
-
Page/Page column 12, (2008/06/13)
Certain substituted butyl and butynyl benzyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.
SUBSTITUTED BENZYL AMINE COMPOUNDS
-
Page/Page column 35, (2008/06/13)
Certain substituted benzyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.
SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS
-
Page/Page column 29-30, (2008/06/13)
Certain substituted aminomethyl benzamide compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.
Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors
Ly, Kiev S.,Letavic, Michael A.,Keith, John M.,Miller, Jennifer M.,Stocking, Emily M.,Barbier, Ann J.,Bonaventure, Pascal,Lord, Brian,Jiang, Xiaohui,Boggs, Jamin D.,Dvorak, Lisa,Miller, Kirsten L.,Nepomuceno, Diane,Wilson, Sandy J.,Carruthers, Nicholas I.
, p. 39 - 43 (2008/09/17)
The synthesis and biological activity of a new series of piperazine and diazepane amides is described. The new compounds are high affinity histamine H3 ligands and serotonin reuptake inhibitors.
Benzylamine histamine H3 antagonists and serotonin reuptake inhibitors
Letavic, Michael A.,Stocking, Emily M.,Barbier, Ann J.,Bonaventure, Pascal,Boggs, Jamin D.,Lord, Brian,Miller, Kirsten L.,Wilson, Sandy J.,Carruthers, Nicholas I.
, p. 4799 - 4803 (2008/03/11)
The design, synthesis, and in vitro activity of a series of novel 5-ethynyl-2-aryloxybenzylamine-based histamine H3 ligands that are also serotonin reuptake transporters is described.
Biaryl ether derivatives useful as monoamine reuptake inhibitors
-
, (2008/06/13)
The present invention relates to compounds of formula I, and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
